{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:13:51Z","timestamp":1767172431759,"version":"build-2238731810"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["17242"],"award-info":[{"award-number":["17242"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Research UK EPSRC","award":["16465"],"award-info":[{"award-number":["16465"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of DCIS, and non-invasive detection of its presence and spatial extent could provide information not obtainable by biopsy. We describe here imaging of the distribution and extent of\n                      <jats:italic>comedo<\/jats:italic>\n                      -type necrosis in a model of human DCIS using C2Am, an imaging agent that binds to the phosphatidylserine exposed by necrotic cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used an established xenograft model of human DCIS that mimics the histopathological features of the disease. Planar near-infrared and optoacoustic imaging, using fluorescently labeled C2Am, were used to image non-invasively the presence and extent of lesion necrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      C2Am showed specific and sensitive binding to necrotic areas in DCIS tissue, detectable both in vivo and ex vivo. The imaging signal generated in vivo using near-infrared (NIR) fluorescence imaging was up to 6-fold higher in DCIS lesions than in surrounding fat pad or skin tissue. There was a correlation between the C2Am NIR fluorescence (Pearson\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.783,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0125) and optoacoustic signals (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009&gt;\u20090.875,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.022) in the DCIS lesions in vivo and the corresponding levels of cell death detected histologically.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>C2Am is a targeted multi-modal imaging agent that could complement current anatomical imaging methods for detecting DCIS. Imaging the presence and spatial extent of necrosis may give better prognostic information than that obtained by biopsy alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-021-01404-z","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T08:02:59Z","timestamp":1613635379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent"],"prefix":"10.1186","volume":"23","author":[{"given":"Zoltan","family":"Szucs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Bohndiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-5166","authenticated-orcid":false,"given":"Andr\u00e9 A.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"1404_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1404_CR2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1089\/pop.2015.29023.mor","volume":"18","author":"E Morris","year":"2015","unstructured":"Morris E, Feig SA, Drexler M, Lehman C. Implications of overdiagnosis: impact on screening mammography practices. Popul Health Manag. 2015;18(Suppl 1):S3.","journal-title":"Popul Health Manag"},{"key":"1404_CR3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1056\/NEJMsr1504363","volume":"372","author":"B Lauby-Secretan","year":"2015","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-cancer screening--viewpoint of the IARC Working Group. N Engl J Med. 2015;372:2353.","journal-title":"N Engl J Med"},{"key":"1404_CR4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jamaoncol.2016.0525","volume":"2","author":"C Shah","year":"2016","unstructured":"Shah C, Wobb J, Manyam B, Kundu N, Arthur D, Wazer D, et al. Management of ductal carcinoma in situ of the breast: a review. JAMA Oncol. 2016;2:1083.","journal-title":"JAMA Oncol"},{"key":"1404_CR5","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ejca.2014.02.023","volume":"50","author":"J Thomas","year":"2014","unstructured":"Thomas J, Hanby A, Pinder SE, Ball G, Lawrence G, Maxwell A, et al. Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur J Cancer. 2014;50:1880.","journal-title":"Eur J Cancer"},{"key":"1404_CR6","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","volume":"24","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ryser MD, Partridge AH, Thompson AM, Thomas JS, Wesseling J, et al. Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017;24:3534.","journal-title":"Ann Surg Oncol"},{"key":"1404_CR7","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205.","journal-title":"Br J Cancer"},{"key":"1404_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CEJ.0000000000000131","volume":"25","author":"X Zhang","year":"2015","unstructured":"Zhang X, Dai H, Liu B, Song F, Chen K. Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev. 2015;25:19.","journal-title":"Eur J Cancer Prev"},{"key":"1404_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/sj.bjc.6605718","volume":"103","author":"SE Pinder","year":"2010","unstructured":"Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR\/ANZ DCIS trial. Br J Cancer. 2010;103:94.","journal-title":"Br J Cancer"},{"key":"1404_CR10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyx059","volume":"47","author":"C Kanbayashi","year":"2017","unstructured":"Kanbayashi C, Iwata H. Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 2017;47:671.","journal-title":"Jpn J Clin Oncol"},{"key":"1404_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-019-05362-1","volume":"178","author":"GS Mannu","year":"2019","unstructured":"Mannu GS, Groen EJ, Wang Z, Schaapveld M, Lips EH, Chung M, et al. Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study. Breast Cancer Res Treat. 2019;178:409.","journal-title":"Breast Cancer Res Treat"},{"key":"1404_CR12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41379-019-0262-4","volume":"32","author":"BT Harrison","year":"2019","unstructured":"Harrison BT, Hwang ES, Partridge AH, Thompson AM, Schnitt SJ. Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Mod Pathol. 2019;32:1257.","journal-title":"Mod Pathol"},{"key":"1404_CR13","first-page":"1","volume":"16","author":"QO Health","year":"2016","unstructured":"Health QO. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment. Ont Health Technol Assess Ser. 2016;16:1.","journal-title":"Ont Health Technol Assess Ser"},{"key":"1404_CR14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/bjs.9797","volume":"102","author":"A Fancellu","year":"2015","unstructured":"Fancellu A, Turner RM, Dixon JM, Pinna A, Cottu P, Houssami N. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. Br J Surg. 2015;102:883.","journal-title":"Br J Surg"},{"key":"1404_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.sult.2017.09.006","volume":"39","author":"J Geisel","year":"2018","unstructured":"Geisel J, Raghu M, Hooley R. The role of ultrasound in breast cancer screening: the case for and against ultrasound. Semin Ultrasound CT MR. 2018;39:25.","journal-title":"Semin Ultrasound CT MR"},{"key":"1404_CR16","doi-asserted-by":"publisher","unstructured":"Boyd NF. Mammographic density and risk of breast cancer. Am Soc Clin Oncol Educ Book. 2013. https:\/\/doi.org\/10.1200\/EdBook_AM.2013.33.e57.","DOI":"10.1200\/EdBook_AM.2013.33.e57"},{"key":"1404_CR17","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.pacs.2019.100144","volume":"16","author":"ABE Attia","year":"2019","unstructured":"Attia ABE, Balasundaram G, Moothanchery M, Dinish US, Bi R, Ntziachristos V, et al. A review of clinical photoacoustic imaging: current and future trends. Photoacoustics. 2019;16:100144.","journal-title":"Photoacoustics."},{"key":"1404_CR18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1038\/s41467-018-04576-z","volume":"9","author":"L Lin","year":"2018","unstructured":"Lin L, Hu P, Shi J, Appleton CM, Maslov K, Li L, et al. Single-breath-hold photoacoustic computed tomography of the breast. Nat Commun. 2018;9:2352.","journal-title":"Nat Commun"},{"key":"1404_CR19","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1007\/s00330-019-06262-0","volume":"29","author":"GLG Menezes","year":"2019","unstructured":"Menezes GLG, Mann RM, Meeuwis C, Bisschops B, Veltman J, Lavin PT, et al. Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers. Eur Radiol. 2019;29:6728.","journal-title":"Eur Radiol"},{"key":"1404_CR20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/bc9004415","volume":"21","author":"IS Alam","year":"2010","unstructured":"Alam IS, Neves AA, Witney TH, Boren J, Brindle KM. Comparison of the C2A domain of Synaptotagmin-I and Annexin-V as probes for detecting cell death. Bioconjug Chem. 2010;21:884.","journal-title":"Bioconjug Chem"},{"key":"1404_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2967\/jnumed.112.114264","volume":"55","author":"AA Neves","year":"2014","unstructured":"Neves AA, Brindle KM. Imaging cell death. J Nucl Med. 2014;55:1.","journal-title":"J Nucl Med"},{"key":"1404_CR22","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1158\/1078-0432.CCR-17-1029","volume":"23","author":"B Xie","year":"2017","unstructured":"Xie B, Tomaszewski MR, Neves AA, Ros S, Hu DE, McGuire S, et al. Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent. Clin Cancer Res. 2017;23:6893.","journal-title":"Clin Cancer Res"},{"key":"1404_CR23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2967\/jnumed.116.183004","volume":"58","author":"AA Neves","year":"2017","unstructured":"Neves AA, Xie B, Fawcett S, Alam IS, Witney TH, de Backer MM, et al. Rapid imaging of tumor cell death in vivo using the C2A domain of Synaptotagmin-I. J Nucl Med. 2017;58:881.","journal-title":"J Nucl Med"},{"key":"1404_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13550-020-00738-7","volume":"10","author":"F Bulat","year":"2020","unstructured":"Bulat F, Hesse F, Hu DE, Ros S, Willminton-Holmes C, Xie B, et al. 18F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography. EJNMMI Res. 2020;10:151.","journal-title":"EJNMMI Res"},{"key":"1404_CR25","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr2358","volume":"11","author":"F Behbod","year":"2009","unstructured":"Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11:R66.","journal-title":"Breast Cancer Res"},{"key":"1404_CR26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/92.14.1185a","volume":"92","author":"FR Miller","year":"2000","unstructured":"Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ [letter]. J Natl Cancer Inst. 2000;92:1185\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"1404_CR27","doi-asserted-by":"crossref","first-page":"872743","DOI":"10.1155\/2013\/872743","volume":"2013","author":"N Barnabas","year":"2013","unstructured":"Barnabas N, Cohen D. Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines. Int J Breast Cancer. 2013;2013:872743.","journal-title":"Int J Breast Cancer"},{"key":"1404_CR28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1073\/pnas.1319000111","volume":"111","author":"PS Patrick","year":"2014","unstructured":"Patrick PS, Hammersley J, Loizou L, Kettunen MI, Rodrigues TB, Hu DE, et al. Dual-modality gene reporter for in vivo imaging. Proc Natl Acad Sci U S A. 2014;111:415.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1404_CR29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555.","journal-title":"Br J Cancer"},{"key":"1404_CR30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2967\/jnumed.116.182311","volume":"58","author":"J Joseph","year":"2017","unstructured":"Joseph J, Tomaszewski MR, Quiros-Gonzalez I, Weber J, Brunker J, Bohndiek SE. Evaluation of precision in optoacoustic tomography for preclinical imaging in living subjects. J Nucl Med. 2017;58:807.","journal-title":"J Nucl Med"},{"key":"1404_CR31","doi-asserted-by":"crossref","first-page":"36021","DOI":"10.1117\/1.JBO.19.3.036021","volume":"19","author":"A Dima","year":"2014","unstructured":"Dima A, Burton NC, Ntziachristos V. Multispectral optoacoustic tomography at 64, 128, and 256 channels. J Biomed Opt. 2014;19:36021.","journal-title":"J Biomed Opt"},{"key":"1404_CR32","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1158\/0008-5472.CAN-19-0182","volume":"79","author":"RL Hesketh","year":"2019","unstructured":"Hesketh RL, Wang J, Wright AJ, Lewis DY, Denton AE, Grenfell R, et al. Magnetic resonance imaging is more sensitive than PET for detecting treatment-induced cell death-dependent changes in glycolysis. Cancer Res. 2019;79:3557.","journal-title":"Cancer Res"},{"key":"1404_CR33","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jnci\/85.21.1725","volume":"85","author":"FR Miller","year":"1993","unstructured":"Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst. 1993;85:1725.","journal-title":"J Natl Cancer Inst"},{"key":"1404_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2002.tb00094.x","volume":"15","author":"J Grabarek","year":"2002","unstructured":"Grabarek J, Amstad P, Darzynkiewicz Z. Use of fluorescently labeled caspase inhibitors as affinity labels to detect activated caspases. Hum Cell. 2002;15:1.","journal-title":"Hum Cell"},{"key":"1404_CR35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s13402-013-0138-4","volume":"36","author":"JF Vermeulen","year":"2013","unstructured":"Vermeulen JF, van der Wall E, Witkamp AJ, van Diest PJ. Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cell Oncol (Dordr). 2013;36:333.","journal-title":"Cell Oncol (Dordr)"},{"key":"1404_CR36","volume":"14","author":"JR Benson","year":"2013","unstructured":"Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol. 2013;14:e348.","journal-title":"Lancet Oncol."},{"key":"1404_CR37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-013-2635-6","volume":"140","author":"AS van Brussel","year":"2013","unstructured":"van Brussel AS, Adams A, Vermeulen JF, Oliveira S, van der Wall E, Mali WP, et al. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;140:263.","journal-title":"Breast Cancer Res Treat"},{"key":"1404_CR38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s004280000267","volume":"437","author":"G Bussolati","year":"2000","unstructured":"Bussolati G, Bongiovanni M, Cassoni P, Sapino A. Assessment of necrosis and hypoxia in ductal carcinoma in situ of the breast: basis for a new classification. Virchows Arch. 2000;437:360.","journal-title":"Virchows Arch"},{"key":"1404_CR39","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70292-4","volume":"14","author":"M van Kruchten","year":"2013","unstructured":"van Kruchten M, de Vries EGE, Brown M, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:e465.","journal-title":"Lancet Oncol"},{"key":"1404_CR40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2967\/jnumed.114.147579","volume":"56","author":"M van Kruchten","year":"2015","unstructured":"van Kruchten M, de Vries EF, Arts HJ, Jager NM, Bongaerts AH, Glaudemans AW, et al. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16\u03b1-18F-fluoro-17\u03b2-estradiol PET\/CT. J Nucl Med. 2015;56:50.","journal-title":"J Nucl Med"},{"key":"1404_CR41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5858\/134.6.907","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907.","journal-title":"Arch Pathol Lab Med"},{"key":"1404_CR42","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/01.pap.0000184177.65919.5e","volume":"12","author":"S Nofech-Mozes","year":"2005","unstructured":"Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol. 2005;12:256.","journal-title":"Adv Anat Pathol"},{"key":"1404_CR43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djp482","volume":"102","author":"BA Virnig","year":"2010","unstructured":"Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170.","journal-title":"J Natl Cancer Inst"},{"key":"1404_CR44","unstructured":"Harris JR, Lippman ME, Morrow MM, Osborne CK. Diseases of the breast. Philadelphia: Wolters Kluwer Health Adis (ESP); 2014."},{"key":"1404_CR45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0140-6736(95)90982-6","volume":"345","author":"MJ Silverstein","year":"1995","unstructured":"Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154.","journal-title":"Lancet."},{"key":"1404_CR46","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.1993.11.10.1929","volume":"11","author":"KW Gilchrist","year":"1993","unstructured":"Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993;11:1929.","journal-title":"J Clin Oncol"},{"key":"1404_CR47","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M. Do LORIS trial eligibility criteria identify a ductal carcinoma in situ patient population at low risk of upgrade to invasive carcinoma. Ann Surg Oncol. 2016;23:3487.","journal-title":"Ann Surg Oncol"},{"key":"1404_CR48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer. 2015;51:1497.","journal-title":"Eur J Cancer"},{"key":"1404_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10911-005-5400-6","volume":"10","author":"MP Morgan","year":"2005","unstructured":"Morgan MP, Cooke MM, McCarthy GM. Microcalcifications associated with breast cancer: an epiphenomenon or biologically significant feature of selected tumors? J Mammary Gland Biol Neoplasia. 2005;10:181.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1404_CR50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJMoa062790","volume":"356","author":"NF Boyd","year":"2007","unstructured":"Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s13058-021-01414-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000}}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-021-01404-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T21:53:44Z","timestamp":1627682024000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-021-01404-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1404"],"URL":"https:\/\/doi.org\/10.1186\/s13058-021-01404-z","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13058-021-01414-x","URL":"https:\/\/doi.org\/10.1186\/s13058-021-01414-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C2Am is under a licensing agreement with Cambridge Enterprise and has been patented (US2011\/0038798). Some of the authors of this study (AAN and KMB) are co-inventors on this patent. No other potential conflict of interest relevant to this article was reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}